DOCSLIB.ORG

Download Product Catalog

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Download Product Catalog Total Quality Medications Product Portfolio Rx Product name Dosage form Generic name Pack size Indications A- Alimentary tract and metabolism A02B – Proton pump inhibitor Omecarbex 20 mg H.G Cap Omeprazole +Na 20 Caps Acid reflux and Ulcers Omecarbex 40 mg H.G Cap Carbonate 20 Caps Acid reflux and Ulcers A06A - Laxatives Amiprostone 8 mcg S.G Cap Lubiprostone 20 Capsules Laxative Amiprostone 24 mcg S.G Cap Lubiprostone 10 Capsules Laxative A07A- Intestinal Anti-infective Anti-diarrheal Gastrobiotic 200 mg Tablets Rifiximin 20 Tablets Antidiarrheal Gastrobiotic 550 mg Tablets Rifiximin 30 Tablets Antidiarrheal Nitazode 100 mg/5 ml Suspension Nitazoxanide Bottle 60 ml Antiprotozoal A10B- Oral Anti -diabetics A10-BD - Oral hypoglycemic associations Glimepiride+ Improve glycemic control for type 2 Glimepiride plus 4/30 Tablets 30 Tablets Pioglitazone Hcl diabetes Glimepiride+ Improve glycemic control for type 2 Glimepiride plus 2/30 Tablets 30 Tablets Pioglitazone Hcl diabetes Metformin Hcl + Improve glycemic control for type 2 Bioglitaplus 15/500 Tablets 20 Tablets Pioglitazone Hcl diabetes Metformin Hcl + Improve glycemic control for type 2 Bioglitaplus 15/850 Tablets 20 Tablets Pioglitazone Hcl diabetes A10BX - Other anti diabetics Control the elevation of blood sugar Megy One 10 mg Tablets Mitiglinide 20 Tablets after eating B- Blood and blood forming organs B01A - Anti-thrombotic agents Andorivaban 10 mg F.C Tablets Rivaroxaban 20 Tablets Anticoagulants Andorivaban 15 mg F.C Tablets Rivaroxaban 20 Tablets Anticoagulants Andorivaban 20 mg F.C Tablets Rivaroxaban 20 Tablets Anticoagulants Andorivaban 2.5 mg F.C Tablets Rivaroxaban 20 Tablets Anticoagulants C- Cardiovascular System C01B - Anti-arrhythmic Vasodarone 400 mg Tablets Dronedarone Hcl 20 Tablets Anti-arrhythmic C03C - High - ceiling Diuretics Cardiotimide 5 mg Tablets Torsemide 20 Tablets Diuretic Cardiotimide 20 mg Tablets Torsemide 20 Tablets Diuretic Cardiotimide 20 mg/2 ml Injection Torsemide 3 Amp Diuretic C08C - Selective calcium channel blockers with mainly vascular effects Blokadipine 10mg F.C Tablets Lercanidipine Hcl 20 Tablets Antihypertensive Blokadipine 20mg F.C Tablets Lercanidipine Hcl 20 Tablets Antihypertensive C09B - Angiotensin - Converting Enzyme (ACE) inhibitors, Combinations Protectopril 8mg Tablets Perindopril Erbumine 20 Tablets Antihypertensive Perindopril + Protectopril 4/1.25 Plus Tablets 20 Tablets Antihypertensive Indapamide C09D - Angiotensin II Antagonists, Combinations Olmespironova 20/12.5 Tablets Olmesartan 30 Tablets Antihypertensive Medoxomil+ Olmespironova 20/25 Tablets Hydrochlorothiazide 30 Tablets Antihypertensive www.alandalous.org 2 Product name Dosage form Generic name Pack size Indications C10A - Cholesterol and triglyceride reducers Andocholest 625 mg F.C Tablets Colesevelam Hcl 20 Tablets Antihyperlipidimic Atorvastatin Ca + Lipicontrol 10/10 F.C Tablets 20 Tablets Antihyperlipidimic Ezetimibe Atorvastatin Ca + Lipicontrol 10/20 F.C Tablets 20 Tablets Antihyperlipidimic Ezetimibe Atorvastatin Ca + Lipicontrol 10/40 F.C Tablets 20 Tablets Antihyperlipidimic Ezetimibe Atorvastatin Ca + Lipicontrol 10/80 F.C Tablets 20 Tablets Antihyperlipidimic Ezetimibe D-Dermatological D05A - Anti-psoriasis for Topical use Zarotex 0.1% Gel Tazarotene Tube - 15 gm Psoriasis, Acne & photo aging D10BA- Anti-acne preparations for systemic use Treatment of moderate to severe Net Look 10 mg Capsules Isotretinion 20 Tablets acne Treatment of moderate to severe Net Look 20 mg Capsules Isotretinion 20 Tablets acne Treatment of moderate to severe Net Look 40 mg Capsules Isotretinion 20 Tablets acne D11AX - Other dermatological preparations Performa 5% Extra strength Solution Minoxidil Bottle - 60 ml Hair re-growth formula G - Genito -Urinary system and sex hormones G04B - Other Urological including Anti-spasmodic Andopoxetine 30 mg Tablets Dapoxetine 3 Tablets Premature ejaculation Andopoxetine 60 mg Tablets Dapoxetine 3 Tablets Premature ejaculation Tadalafil 20 mg F.C Tab Tadalafil 10 Tablets Erectile dysfunction Darifenacin Andodaracine 7.5 mg Tablets 20 Tablets Urinary Antispasmodic Hydrobromide Sildocare 4mg Capsules Silodosin 20 Capsules Benign prostatic hyperplasia Sildocare 8mg Capsules Silodosin 20 Capsules Benign prostatic hyperplasia Erovanafile 100mg Tablets Avanafil 4 Tablets Erectile dysfunction Erovanafile 200mg Tablets Avanafil 4 Tablets Erectile dysfunction Andagra 100 mg Tablets Sildenafil 4 Tablets Erectile dysfunction H-Systemic hormonal preparations (excluding sex hormones) H02A - Corticosteroids for systemic use, plain Prednisolone m Disprelone-D 20 mg Dispersible Tablets 20 Tablets Corticosteroid therapy sodium bisulphide J- General Anti-infective , Systemic J01C - Beta-lactam Antibacterial , Penicillin Powder for Amoxicillin + Respiratory, urinary and soft tissue Newclav 457 Bottle -80 ml suspension clavulanic acid infections Powder for Amoxicillin + Respiratory, urinary and soft tissue Newclav 642.9 Extra strength Bottle 50,100 ml suspension clavulanic acid infections J05A -Agents affecting the virus directly , excluding vaccines Andohepsubvir 400 mg Tablets Sofosbuvir 28 Tablets Hepatitis C treatment L-Antineoplastic and immunodulating agents L04A - Immunosuppressive agents Tarolimus 0.03% Ointment Tacrolimus Tube - 15 gm Atropic Dermatitis www.alandalous.org 3 Product name Dosage form Generic name Pack size Indications M- Musculo- skeletal system M01A - Anti-inflammatory et anti-rheumatic products, non steroids Extragesic 400mg Tablets Dexiibuprofen 20 Tablets Anti-rheumatic et anti-inflammatory M04A - Anti-gout preparations Andouristat 80 mg Tablets Febuxostat 20 Tablets Chronic hyperuricemia Andouristat 120 mg Tablets Febuxostat 20 Tablets Chronic hyperuricemia N-Central Nervous System N03A - Anti-epileptics Tiratam 500 mg Tablets Levetiracetam 20 Tablets Antiepileptic Tiratam 500 mg XR Tablets Levetiracetam 20 Tablets Antiepileptic Tiratam 750 mg Tablets Levetiracetam 20 Tablets Antiepileptic Tiratam 750 mg XR Tablets Levetiracetam 20 Tablets Antiepileptic Tiratam 1000 mg Tablets Levetiracetam 20 Tablets Antiepileptic Tiratam 100 mg/ml Suspension Levetiracetam Bottle - 120 ml Antiepileptic Tiratam 100 mg/ml Injection Levetiracetam 1 Vial Antiepileptic Antiepileptic, migraine Divakote 500 mg Tablets Divalproex sodium 20 Tablets et schizophrenia Antiepileptic, migraine Divakote 250 mg Tablets Divalproex sodium 20 Tablets et schizophrenia Andogablin 75 mg Capsules Pregabalin 20 capsules Neuropathic pain Andogablin 150 mg Capsules Pregabalin 20 capsules Neuropathic pain Andovimpamide 100 mg F.C Tablets Lacosamide 20 Tablets Antiepileptic Andovimpamide 100 mg F.C Tablets Lacosamide 20 Tablets Antiepileptic Andovimpamide Solution Lacosamide 20 Tablets Antiepileptic Andovimpamide Injection Lacosamide 20 Tablets Antiepileptic Eslizepine 400 mg Tablets Eslicarbazepine Acetate 20 Tablets Antiepileptic Eslizepine 800 mg Tablets Eslicarbazepine Acetate 20 Tablets Antiepileptic Andoxesine 150 mg F.C Tablets Oxycarbazepine 10 Tablets Antiepileptic Andoxesine 300 mg F.C Tablets Oxycarbazepine 10 Tablets Antiepileptic N04B - Dopaminergic agents Parkicapone 200 mg F.C Tablets Entacapone 20 Tablets Adjuvant therapy for parkinsonism Parkidopa 200 mg/50 mg C.R. Tablets Levodopa + Carbidopa 20 Tablets Treatment of parkinsonism N05A- Anti-psychotics Aripiprex 10mg Tablets Aripiprazole 20 Tablets Schizophrenia and bipolar disorder Aripiprex 30mg Tablets Aripiprazole 10 Tablets Schizophrenia and bipolar disorder Aripiprex 1mg/ml Syrup Aripiprazole Bottle - 100 ml Schizophrenia and bipolar disorder Aripiprex 7.5 ml/ml Injection Aripiprazole 3 Vials Schizophrenia and bipolar disorder Andequepine 200Mg Xr Tablets Quetiapine Fumarate 20 Tab Schizophrenia and bipolar disorder www.alandalous.org 4 Product name Dosage form Generic name Pack size Indications Amipride 50 mg Tablets Amisulpride 20 Tablets Antipsychotic Amipride 100 mg Tablets Amisulpride 20 Tablets Antipsychotic Amipride 200 mg Tablets Amisulpride 20 Tablets Antipsychotic Amipride 400 mg Tablets Amisulpride 20 Tablets Antipsychotic N05C - Hypnotics et sedatives Siesta 10 mg Capsules Zaleplon 14 Capsules Non benzodiazepine hypnotic N06A - Anti-depressants Durazac weekly 90 mg Capsules Fluoxetine 4 Capsules Antidepressant Depretrive 20 mg Capsules Duloxetine 20 Caps For depression and anxiety R-Respiratory System R01A – Decongestants & other nasal preparations for topical use Nosemys Nasal Spray Fluticasone Furoate Bottle - 10 ml Allergic rhinitis R05C - Expectorants , excl. combinations with cough suppressants Erdolytic 300 mg Capsules Erdosteine 20 Capsules Mucolytic Food supplements Dr Diet Tablets Sucralose 100 Tablets No calories sweetener Dr Diet Sachets Sucralose 50 sachets No calories sweetener OTC Cosmetics Andoderma SPF +50 Cream Maximum protection Tube -50 gm Sunscreen Andoderma SPF + 42 Lotion Maximum protection Tube- 150 gm Sunscreen Highly Emollient & protective Andoderma Extra Emollient Gel Tube - 50 ml Skin Emollient Gel hydrating base Highly Emollient & protective Tube – 50 gm , Skin soothing after Andoderma Multi care Cream hydrating base 125 gm exposure to sun Bottle - 75 ml , Cleandex Extra Hand Gel For dry cleaning of dirt’s Hand cleansing gel 500 ml with pump Jungle alcohol free Mouth wash Alcohol free mouth wash Bottle -225 ml Mouth wash Stripsore Lozenges Honey & lemon flavor 24 Lozenges Sore throat Stripsore Sugar free Lozenges Sugar free 24 Lozenges Sore throat Stripsore Vit C Lozenges Sugar free 24 Lozenges Sore throat Oilex Cream Highly Emollient 50 gm Skin Emollient cream Sinsin Pas Gel patch Patch Cooling effect Box – 4 pieces Muscular pain Sinsin Pas Icy patch Patch Cool hydro Gel Box – 4 pieces Pain Relief Hotness & counter irritant Sinsin Pas Capsicum patch Patch Box - 4 pieces Pain Relief effect Scientific office: Factory: Villa 52, Street 104, Maadi, Cairo, Egypt. Lot No. 7/6, 6th industrial area, 6th of October city, Tel: +202-25275508/9 | Fax: +202-25275506 Egypt. Tel: +202-38243257/8/9 | Fax: +202-38243441 Email: [email protected] Website: www.alandalous.org 5 .
Load more

Recommended publications
  • Specifications of Approved Drug Compound Library
    Annexure-I : Specifications of Approved drug compound library The compounds should be structurally diverse, medicinally active, and cell permeable Compounds should have rich documentation with structure, Target, Activity and IC50 should be known Compounds which are supplied should have been validated by NMR and HPLC to ensure high purity Each compound should be supplied as 10mM solution in DMSO and at least 100µl of each compound should be supplied. Compounds should be supplied in screw capped vial arranged as 96 well plate format.
    [Show full text]
  • Stems for Nonproprietary Drug Names
    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
    [Show full text]
  • Sulfonylurea Stimulation of Insulin Secretion Peter Proks,1 Frank Reimann,2 Nick Green,1 Fiona Gribble,2 and Frances Ashcroft1
    Sulfonylurea Stimulation of Insulin Secretion Peter Proks,1 Frank Reimann,2 Nick Green,1 Fiona Gribble,2 and Frances Ashcroft1 Sulfonylureas are widely used to treat type 2 diabetes smooth, and skeletal muscle, and some brain neurones. In because they stimulate insulin secretion from pancre- all these tissues, opening of KATP channels in response to atic ␤-cells. They primarily act by binding to the SUR metabolic stress leads to inhibition of electrical activity. subunit of the ATP-sensitive potassium (KATP) channel Thus they are involved in the response to both cardiac and and inducing channel closure. However, the channel is cerebral ischemia (2). They are also important in neuronal still able to open to a limited extent when the drug is regulation of glucose homeostasis (3), seizure protection bound, so that high-affinity sulfonylurea inhibition is not complete, even at saturating drug concentrations. (4), and the control of vascular smooth muscle tone (and, thereby, blood pressure) (5). KATP channels are also found in cardiac, skeletal, and smooth muscle, but in these tissues are composed of The KATP channel is a hetero-octameric complex of two different SUR subunits that confer different drug different types of protein subunits: an inwardly rectifying sensitivities. Thus tolbutamide and gliclazide block Kϩ channel, Kir6.x, and a sulfonylurea receptor, SUR (6,7). ␤ ϩ channels containing SUR1 ( -cell type), but not SUR2 Kir6.x belongs to the family of inwardly rectifying K (cardiac, smooth muscle types), whereas glibenclamide, (Kir) channels and assembles as a tetramer to form the glimepiride, repaglinide, and meglitinide block both types of channels.
    [Show full text]
  • Pharmacokinetic and Pharmacodynamic Modeling of Oral
    Liu et al. BMC Pharmacology and Toxicology (2017) 18:54 DOI 10.1186/s40360-017-0161-6 RESEARCH ARTICLE Open Access Pharmacokinetic and pharmacodynamic modeling of oral mitiglinide on glucose lowering in healthy Chinese volunteers Shijia Liu1, Peidong Chen2, Yang Zhao3, Guoliang Dai1, Bingting Sun2, Yao Wang1, Anwei Ding2 and Wenzheng Ju1* Abstract Background: Mitiglinide is a widely used agent for diabetic treatment. We established a pharmacokinetic- pharmacodynamic (PK-PD) model to illustrate the relationship between mitiglinide plasma concentration and its glucose lowering effects in healthy volunteers. Methods: The volunteers participated in the test after the administration of a single dose of 10 mg mitiglinide. The drug concentration in Plasma and the values of glucose levels were determined by LC-MS/MS assay and hexokinase method. A PK-PD model was established with a series of equations to describe the relationship between plasma medicine and glucose, and the equations were solved numerically and fitted to the data with the Phoenix NLME software. Results: The results of the two-compartment model analysis were based on the maximum likelihood criterion and visual inspection of the fittings. The terminal elimination half-life (t1/2) was 1.69 ± 0.16 h and the CL/F was 7.80 ± 1.84 L/h. The plasma glucose levels began to decline by 0.2 h, and hit its bottom decreasing values of 2.6 mg/L at 0.5 h after administration. The calculated parameter and fitting curve indicated that the model established in our experiment fitted well. Conclusions: A PK/PD model illustrates that the relationship between mitiglinide concentration in plasma and glucose lowering effect in healthy volunteers was established.
    [Show full text]
  • Jp Xvii the Japanese Pharmacopoeia
    JP XVII THE JAPANESE PHARMACOPOEIA SEVENTEENTH EDITION Official from April 1, 2016 English Version THE MINISTRY OF HEALTH, LABOUR AND WELFARE Notice: This English Version of the Japanese Pharmacopoeia is published for the convenience of users unfamiliar with the Japanese language. When and if any discrepancy arises between the Japanese original and its English translation, the former is authentic. The Ministry of Health, Labour and Welfare Ministerial Notification No. 64 Pursuant to Paragraph 1, Article 41 of the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices (Law No. 145, 1960), the Japanese Pharmacopoeia (Ministerial Notification No. 65, 2011), which has been established as follows*, shall be applied on April 1, 2016. However, in the case of drugs which are listed in the Pharmacopoeia (hereinafter referred to as ``previ- ous Pharmacopoeia'') [limited to those listed in the Japanese Pharmacopoeia whose standards are changed in accordance with this notification (hereinafter referred to as ``new Pharmacopoeia'')] and have been approved as of April 1, 2016 as prescribed under Paragraph 1, Article 14 of the same law [including drugs the Minister of Health, Labour and Welfare specifies (the Ministry of Health and Welfare Ministerial Notification No. 104, 1994) as of March 31, 2016 as those exempted from marketing approval pursuant to Paragraph 1, Article 14 of the Same Law (hereinafter referred to as ``drugs exempted from approval'')], the Name and Standards established in the previous Pharmacopoeia (limited to part of the Name and Standards for the drugs concerned) may be accepted to conform to the Name and Standards established in the new Pharmacopoeia before and on September 30, 2017.
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • Pharmaceuticals As Environmental Contaminants
    PharmaceuticalsPharmaceuticals asas EnvironmentalEnvironmental Contaminants:Contaminants: anan OverviewOverview ofof thethe ScienceScience Christian G. Daughton, Ph.D. Chief, Environmental Chemistry Branch Environmental Sciences Division National Exposure Research Laboratory Office of Research and Development Environmental Protection Agency Las Vegas, Nevada 89119 [email protected] Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Why and how do drugs contaminate the environment? What might it all mean? How do we prevent it? Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada This talk presents only a cursory overview of some of the many science issues surrounding the topic of pharmaceuticals as environmental contaminants Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada A Clarification We sometimes loosely (but incorrectly) refer to drugs, medicines, medications, or pharmaceuticals as being the substances that contaminant the environment. The actual environmental contaminants, however, are the active pharmaceutical ingredients – APIs. These terms are all often used interchangeably Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Office of Research and Development Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdfNational
    [Show full text]
  • The Claimed Intermediate Online Database | Drug Names to Search: Control F (PC) Command F (Mac) Open & Search in Ibooks App (Ipad)
    The Claimed Intermediate Online Database | Drug Names www.tcipatent.com To search: Control F (PC) Command F (Mac) Open & search in iBooks app (iPad) Drug Name Abiraterone Acetaminophen Adefovir Dipivoxil Agomelatine Albendazole Alendronic acid Alfentanil Aliskiren Allopurinol Almorexant Almotriptan Alogliptin Alosetron Alprostadil Alvimopan www.tcipatent.com Ambrisentan Aminaphtone Amisulpride Amlodipine Amorolfine Amphetamine Amprenavir Amrubicin Amylmetacresol Anagrelide Anastrozole www.tcipatent.com Apixaban Aprepitant Arformoterol Argatroban Aripiprazole Armodafinil Artemether Artemisinin Asenapine Aspirin Atazanavir www.tcipatent.com Atomoxetine Atorvastatin Atorvastatin ( Rosuvastatin Ezetimibe Linezolid ) Atovaquone Azacitidine Azilsartan Azilsartan medoxomil Azithromycin Baclofen Bazedoxifene Bendamustine www.tcipatent.com Benidipine Betaxolol Bexarotene Biapenem Bicalutamide Bimatoprost Bimatoprost ( Latanoprost Travoprost ) Bisoprolol Bivalirudin Boceprevir Bortezomib www.tcipatent.com Bosentan Brinzolamide Bromfenac Buclizine Buprenorphine Bupropion Cabazitaxel Cabazitaxel ( Docetaxel Paclitaxel ) Candesartan cilexetil Capecitabine Carbabenzpyride Caspofungin Cefamandole www.tcipatent.com Cefdinir Cefditoren pivoxil Cefepime Cefixime Cefoperazone Cefotaxime Cefozopran Cefpodoxime Cefpodoxime proxetil Ceftaroline fosamil Ceftobiprole www.tcipatent.com Ceftobiprole medocaril Ceftriaxone Celecoxib Cetirizine Cevimeline Chloroquine Chlorothiazide Cidofovir Cilastatin Cilazapril Cinacalcet www.tcipatent.com Ciprofloxacin Cisatracurium
    [Show full text]
  • Differences Between Mitiglinide/Voglibose Fixed- Dose
    94 Original Article Differences between Mitiglinide/Voglibose Fixed- dose Combination and Glimepiride in Modifying Low- density Lipoprotein Heterogeneity in Japanese Type-2 Diabetic Patients: A Pilot Study Authors S. Tani1, 2, K. Nagao2, A. Hirayama2 Affiliations 1 Department of Health Planning Center, Nihon University Hospital, Tokyo Japan 2 Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Tokyo Japan Key words Abstract nificantly. In the mitiglinide/voglibose group, ●▶ glimepiride ▼ serum LDL-C levels did not change, while sd-LDL ●▶ LDL-heterogeneity Purpose: The purpose of this study was to levels and sd-LDL/LDL-C decreased significantly ●▶ mitiglinide/voglibose ( − 8.6 % and − 7.9 %) and LDL-C/apoB increased ­fixed-dose­combination compare the effects of mitiglinide/voglibose fixed-dose combination and glimepiride on significantly (5.8 %). Fasting blood glucose levels low-density lipoprotein (LDL)-heterogeneity in tended to be reduced to a greater extent in the type-2 diabetic patients with unstable glycemic glimepiride group than in the mitiglinide/voglib- control after treatment with dipeptidyl pepti- ose group ( − 13.9 % vs. − 8.4 %, p = 0.08), while dase-4 (DPP-4) inhibitors. the rate of reduction of HbA1c levels tended Methods: This was an open-label pilot study in to be higher in the mitiglinide/voglibose group which type-2 diabetic patients were randomly than in the glimepiride group ( − 6.9 % vs. − 3.4 %, assigned to the mitiglinide/voglibose (fixed-dose p = 0.09), suggesting differences in fluctuating combination of mitiglinide 10 mg and voglibose blood glucose levels between the 2 groups. 0.2 mg, n = 14) or glimepiride (0.5 mg, n = 16).
    [Show full text]
  • (12) United States Patent (10) Patent N0.: US 7,888,382 B2 Kiyono Et A]
    US007888382B2 (12) United States Patent (10) Patent N0.: US 7,888,382 B2 Kiyono et a]. (45) Date of Patent: Feb. 15, 2011 (54) COMBINED PHARMACEUTICAL 2005/0197376 A1* 9/2005 Kayakiri et al. ........... .. 514/394 PREPARATION FOR TREATMENT OF TYPE 2 DIABETES FOREIGN PATENT DOCUMENTS EP 1 532 979 5/2005 (75) Inventors: Yuji Kiyono, Tokyo (JP); Yoshio JP 2001-316293 11/2001 Okubo, Tokyo (JP); Katsumi Hontani, WO 2007/033292 3/2007 Tokyo (JP); Imao Mikoshiba, Tokyo (JP); Kazuma Ojima, AZumino (JP) OTHER PUBLICATIONS International Search Report issued Jul. 5, 2006 in the International (73) Assignee: Kissei Pharmaceutical Co., Ltd., (PCT) Application of which the present application is the US. Nagano (JP) National Stage. K. Ojima et al., “Pharmacological and Clinical Pro?le of Mitiglinide ( * ) Notice: Subject to any disclaimer, the term of this Calcium Hydrate (Glufast®), A New Insulinotropic Agent With patent is extended or adjusted under 35 Rapid Onset”, Folia Pharmacol. Jpn. (Nippon Yakurigaku Zasshi), 2004, vol. 124, No. 4, pp. 245-255 (English Abstract enclosed). U.S.C. 154(b) by 102 days. K. Ojima et al., “Rapid Onset-Insulinotropic Effect of Mitiglinide Calcium Dihydrate (KAD-1229), A Novel Antipostprandial (21) Appl. No.: 11/918,654 Hyperglycemic Agent”, Jpn. Pharmacol Ther, 2004, vol. 32, No. 2, pp. 73-80. (22) PCT Filed: Apr. 18,2006 R. F. Coniffet al., “Multicenter, Placebo-Controlled Trial Comparing Acarbose (BAY g 5421) With Placebo, Tolbutamide, and (86) PCT No.: PCT/JP2006/308110 Tolbutamide-Plus-Acarbose in Non-Insulin-Dependent Diabetes Mellitus”, The American Journal of Medicine, vol. 98, pp.
    [Show full text]
  • Development and Validation of an LC-MS/MS Method for The
    Printed in the Republic of Korea ANALYTICAL SCIENCE & TECHNOLOGY Vol. 32 No. 2, 35-47, 2019 https://doi.org/10.5806/AST.2019.32.2.35 Development and validation of an LC-MS/MS method for the simultaneous analysis of 26 anti-diabetic drugs in adulterated dietary supplements and its application to a forensic sample Nam Sook Kim†, Geum Joo Yoo†, Kyu Yeon Kim, Ji Hyun Lee, Sung-Kwan Park, Sun Young Baek, and Hoil Kang★ Division of Advanced Analysis, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Osong Health Technology Administration Complex, 187 Osongsaengmyeong2-ro, Osongeup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do 363-700, Korea (Received September 18, 2018; Revised February 21, 2019; Accepted March 7, 2019) Abstract In this study, high-performance liquid chromatography–tandem mass spectrometry (HPLC-MS/ MS) was employed to detect 26 antidiabetic compounds in adulterated dietary supplements using a simple, selective method. The work presented herein may help prevent incidents related to food adulteration and restrict the illegal food market. The best separation was obtained on a Shiseido Capcell Pak® C18 MG- II (2.0 mm × 100 mm, 3 µm), which improved the peak shape and MS detection sensitivity of the target compounds. A gradient elution system composed of 0.1 % (v/v) formic acid in distilled water and methanol at a flow rate of 0.3 mL/min for 18 min was utilized. A triple quadrupole mass spectrometer with an electrospray ionization source operated in the positive or negative mode was employed as the detector. The developed method was validated as follows: specificity was confirmed in the multiple reaction monitoring mode using the precursor and product ion pairs.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]